2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME)

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Introduction. Highly selective inhibitors of phosphodiesterase type 5 (PDE5I) have been commercially available for over a decade. Our knowledge of these drugs continues to expand. Aims. To review developments within the past 18 months on the utilization of PDE5I in preclinical studies and clinical practice. The focus of this article is on updates on regular dosing regimens of PDE5I other than the newly approved daily dose tadalafil. Methods. PubMed search utilizing the terms "phosphodiesterase type 5 inhibitor," PDE5 inhibitor," "sildenafil," "vardenafil," and "tadalafil." Articles were screened based on whether or not they addressed issues of routine dosing of PDE5I. Manuscripts on the newly approved daily dose tadalafil for erectile dysfunction (ED) were deferred for analysis in a separate manuscript in this series. Main Outcome Measures. Peer reviewed publications on routine dosing of PDE5I published in the medical literature since 2007. Results. There have been numerous publications in the past 2 years regarding routine dosing of PDE5I for three major urological indications; penile rehabilitation, stuttering priapism, and management of lower urinary tract symptoms (LUTS). Evidence from basic science investigations has indicated that daily dose PDE5I may improve erectile function and exert a number of beneficial tissue effects on the penis. Unfortunately, data from human series of routine dose PDE5I for penile rehabilitation after radical prostatectomy are conflicting, with the two largest studies showing no benefit to daily dose therapy in the post-radical prostatectomy and the general ED populations. PDE5I are generally helpful at reducing symptoms of LUTS, particularly when given in conjunction with alpha blockers. Routine dosing of PDE5I has also been utilized successfully for management of stuttering ischemic priapism and several other medical indications. Conclusions. PDE5I given as routine doses have clinical promise. Further research is required to clarify their safety and efficacy for various indications.

Original languageEnglish (US)
Pages (from-to)1794-1808
Number of pages15
JournalJournal of Sexual Medicine
Volume6
Issue number7
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Phosphodiesterase 5 Inhibitors
Lower Urinary Tract Symptoms
Priapism
Stuttering
Rehabilitation
Manuscripts
Erectile Dysfunction
Prostatectomy
Publications
Penis
PubMed
Therapeutics
Outcome Assessment (Health Care)
Safety
Research
Pharmaceutical Preparations
Population
Tadalafil

Keywords

  • Daily dosing
  • Erectile dysfunction
  • Lower urinary tract symptoms
  • Penile rehabilitation
  • Phosphodiesterase type 5 inhibitors
  • Stuttering priapism

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynecology
  • Reproductive Medicine
  • Medicine(all)

Cite this

@article{4d578b0f59224999a96c0ef7638a4b3e,
title = "2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME)",
abstract = "Introduction. Highly selective inhibitors of phosphodiesterase type 5 (PDE5I) have been commercially available for over a decade. Our knowledge of these drugs continues to expand. Aims. To review developments within the past 18 months on the utilization of PDE5I in preclinical studies and clinical practice. The focus of this article is on updates on regular dosing regimens of PDE5I other than the newly approved daily dose tadalafil. Methods. PubMed search utilizing the terms {"}phosphodiesterase type 5 inhibitor,{"} PDE5 inhibitor,{"} {"}sildenafil,{"} {"}vardenafil,{"} and {"}tadalafil.{"} Articles were screened based on whether or not they addressed issues of routine dosing of PDE5I. Manuscripts on the newly approved daily dose tadalafil for erectile dysfunction (ED) were deferred for analysis in a separate manuscript in this series. Main Outcome Measures. Peer reviewed publications on routine dosing of PDE5I published in the medical literature since 2007. Results. There have been numerous publications in the past 2 years regarding routine dosing of PDE5I for three major urological indications; penile rehabilitation, stuttering priapism, and management of lower urinary tract symptoms (LUTS). Evidence from basic science investigations has indicated that daily dose PDE5I may improve erectile function and exert a number of beneficial tissue effects on the penis. Unfortunately, data from human series of routine dose PDE5I for penile rehabilitation after radical prostatectomy are conflicting, with the two largest studies showing no benefit to daily dose therapy in the post-radical prostatectomy and the general ED populations. PDE5I are generally helpful at reducing symptoms of LUTS, particularly when given in conjunction with alpha blockers. Routine dosing of PDE5I has also been utilized successfully for management of stuttering ischemic priapism and several other medical indications. Conclusions. PDE5I given as routine doses have clinical promise. Further research is required to clarify their safety and efficacy for various indications.",
keywords = "Daily dosing, Erectile dysfunction, Lower urinary tract symptoms, Penile rehabilitation, Phosphodiesterase type 5 inhibitors, Stuttering priapism",
author = "Shindel, {Alan W}",
year = "2009",
doi = "10.1111/j.1743-6109.2009.01347.x",
language = "English (US)",
volume = "6",
pages = "1794--1808",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - 2009 update on phosphodiesterase type 5 inhibitor therapy part 1

T2 - Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME)

AU - Shindel, Alan W

PY - 2009

Y1 - 2009

N2 - Introduction. Highly selective inhibitors of phosphodiesterase type 5 (PDE5I) have been commercially available for over a decade. Our knowledge of these drugs continues to expand. Aims. To review developments within the past 18 months on the utilization of PDE5I in preclinical studies and clinical practice. The focus of this article is on updates on regular dosing regimens of PDE5I other than the newly approved daily dose tadalafil. Methods. PubMed search utilizing the terms "phosphodiesterase type 5 inhibitor," PDE5 inhibitor," "sildenafil," "vardenafil," and "tadalafil." Articles were screened based on whether or not they addressed issues of routine dosing of PDE5I. Manuscripts on the newly approved daily dose tadalafil for erectile dysfunction (ED) were deferred for analysis in a separate manuscript in this series. Main Outcome Measures. Peer reviewed publications on routine dosing of PDE5I published in the medical literature since 2007. Results. There have been numerous publications in the past 2 years regarding routine dosing of PDE5I for three major urological indications; penile rehabilitation, stuttering priapism, and management of lower urinary tract symptoms (LUTS). Evidence from basic science investigations has indicated that daily dose PDE5I may improve erectile function and exert a number of beneficial tissue effects on the penis. Unfortunately, data from human series of routine dose PDE5I for penile rehabilitation after radical prostatectomy are conflicting, with the two largest studies showing no benefit to daily dose therapy in the post-radical prostatectomy and the general ED populations. PDE5I are generally helpful at reducing symptoms of LUTS, particularly when given in conjunction with alpha blockers. Routine dosing of PDE5I has also been utilized successfully for management of stuttering ischemic priapism and several other medical indications. Conclusions. PDE5I given as routine doses have clinical promise. Further research is required to clarify their safety and efficacy for various indications.

AB - Introduction. Highly selective inhibitors of phosphodiesterase type 5 (PDE5I) have been commercially available for over a decade. Our knowledge of these drugs continues to expand. Aims. To review developments within the past 18 months on the utilization of PDE5I in preclinical studies and clinical practice. The focus of this article is on updates on regular dosing regimens of PDE5I other than the newly approved daily dose tadalafil. Methods. PubMed search utilizing the terms "phosphodiesterase type 5 inhibitor," PDE5 inhibitor," "sildenafil," "vardenafil," and "tadalafil." Articles were screened based on whether or not they addressed issues of routine dosing of PDE5I. Manuscripts on the newly approved daily dose tadalafil for erectile dysfunction (ED) were deferred for analysis in a separate manuscript in this series. Main Outcome Measures. Peer reviewed publications on routine dosing of PDE5I published in the medical literature since 2007. Results. There have been numerous publications in the past 2 years regarding routine dosing of PDE5I for three major urological indications; penile rehabilitation, stuttering priapism, and management of lower urinary tract symptoms (LUTS). Evidence from basic science investigations has indicated that daily dose PDE5I may improve erectile function and exert a number of beneficial tissue effects on the penis. Unfortunately, data from human series of routine dose PDE5I for penile rehabilitation after radical prostatectomy are conflicting, with the two largest studies showing no benefit to daily dose therapy in the post-radical prostatectomy and the general ED populations. PDE5I are generally helpful at reducing symptoms of LUTS, particularly when given in conjunction with alpha blockers. Routine dosing of PDE5I has also been utilized successfully for management of stuttering ischemic priapism and several other medical indications. Conclusions. PDE5I given as routine doses have clinical promise. Further research is required to clarify their safety and efficacy for various indications.

KW - Daily dosing

KW - Erectile dysfunction

KW - Lower urinary tract symptoms

KW - Penile rehabilitation

KW - Phosphodiesterase type 5 inhibitors

KW - Stuttering priapism

UR - http://www.scopus.com/inward/record.url?scp=67649887476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649887476&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2009.01347.x

DO - 10.1111/j.1743-6109.2009.01347.x

M3 - Article

C2 - 19575771

AN - SCOPUS:67649887476

VL - 6

SP - 1794

EP - 1808

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 7

ER -